Posaconazole Plasma Monitoring in Immunocompromised Children | Zendy

Jessica McMahon | Zendy; Yves Théorêt | Zendy; Julie Autmizguine | Zendy; Henrique Bittencourt | Zendy; Bruce Tapiéro | Zendy; Philippe Ovetchkine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Posaconazole Plasma Monitoring in Immunocompromised Children

Author(s) -

Jessica McMahon,

Yves Théorêt,

Julie Autmizguine,

Henrique Bittencourt,

Bruce Tapiéro,

Philippe Ovetchkine

Publication year - 2016

Publication title -

journal of the pediatric infectious diseases society

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piw087

Subject(s) - posaconazole , medicine , plasma concentration , hematopoietic stem cell transplantation , plasma levels , hematopoietic cell , stem cell , transplantation , haematopoiesis , antifungal , itraconazole , dermatology , biology , genetics

Plasma posaconazole exposure was assessed in 13 children who underwent a hematopoietic stem cell transplant. The median dosage was 12.5 mg/kg per day, divided into 3 doses. Of these 13 patients, 46.2% (6) and 30.8% (4) achieved concentrations higher than 0.7 and 1.25 mg/L, respectively. In children at high risk, a higher dosage might be needed to achieve target concentrations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research